Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung Phase 2 Study Evaluating Namilumab For Chronic Pulmonary Sarcoidosis
Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung Phase 2 Study Evaluating Namilumab For Chronic Pulmonary Sarcoidosis
Roivant和Kinevant Sciences完成了評估納米魯單抗治療慢性肺結節病的Resolve-Lung 2期研究的入組
Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung Phase 2 Study Evaluating Namilumab For Chronic Pulmonary Sarcoidosis
Roivant和Kinevant Sciences完成了評估納米魯單抗治療慢性肺結節病的Resolve-Lung 2期研究的入組
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。